We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
Cap. Flow
+$155M
Cap. Flow %
40.41%
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.5M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$7.89M
5
ARGX icon
argenx
ARGX
+$7.32M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$9.05M
2
ABBV icon
AbbVie
ABBV
+$8.88M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

Rank Sector Weight
1 Healthcare 32.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
51
DELISTED
KalVista Pharmaceuticals
KALV
$1.56M 0.41%
+135,509
New +$1.38M
KROS icon
52
CALL
Keros Therapeutics
KROS
$200M
$1.5M 0.39%
147,100
+17,100
+13% +$199K
APGE icon
53
Apogee Therapeutics
APGE
$10.1B
$1.49M 0.39%
40,000
-10,620
-21% -$411K
MRNA icon
54
CALL
Moderna
MRNA
$21.9B
$1.48M 0.39%
+52,100
New +$1.85M
SAGE
55
DELISTED
Sage Therapeutics
SAGE
$1.46M 0.38%
+183,466
New +$1.34M
VTGN icon
56
VistaGen Therapeutics
VTGN
$10.1M
$1.41M 0.37%
565,975
+123,455
+28% +$349K
ASND icon
57
Ascendis Pharma A/S
ASND
$16B
$1.3M 0.34%
8,321
-16,955
-67% -$2.42M
VKTX icon
58
CALL
Viking Therapeutics
VKTX
$3.8B
$1.21M 0.32%
+50,000
New +$1.58M
COGT icon
59
PUT
Cogent Biosciences
COGT
$6.64B
$1.21M 0.31%
+201,400
New +$1.58M
KALV
60
CALL
DELISTED
KalVista Pharmaceuticals
KALV
$1.19M 0.31%
+103,300
New +$1.05M
MREO
61
CALL
Mereo BioPharma
MREO
$50.4M
$1.16M 0.3%
+515,200
New +$1.46M
TRVI icon
62
Trevi Therapeutics
TRVI
$2.54B
$1.13M 0.3%
+180,000
New +$859K
RLAY icon
63
Relay Therapeutics
RLAY
$4.09B
$1.12M 0.29%
426,346
-79,432
-16% -$311K
FOLD
64
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.07M 0.28%
131,400
+31,400
+31% +$291K
OCUL icon
65
CALL
Ocular Therapeutix
OCUL
$1.84B
$1M 0.26%
136,700
+32,700
+31% +$251K
PCRX icon
66
Pacira BioSciences
PCRX
$1.06B
$967K 0.25%
+38,926
New +$932K
GOSS icon
67
CALL
Gossamer Bio
GOSS
$84.9M
$907K 0.24%
824,800
+567,900
+221% +$656K
URGN icon
68
UroGen Pharma
URGN
$1.88B
$843K 0.22%
76,220
+26,220
+52% +$280K
CLYM
69
Climb Bio
CLYM
$676M
$817K 0.21%
669,803
+295,380
+79% +$479K
CYTK icon
70
Cytokinetics
CYTK
$10.4B
$804K 0.21%
+20,000
New +$919K
REPL icon
71
Replimune Group
REPL
$1B
$727K 0.19%
74,530
-39,470
-35% -$488K
KROS icon
72
PUT
Keros Therapeutics
KROS
$200M
$671K 0.17%
65,800
+15,400
+31% +$179K
CRDF icon
73
CALL
Cardiff Oncology
CRDF
$72.7M
$653K 0.17%
+208,100
New +$823K
RVPH
74
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$621K 0.16%
+32,536
New +$1.02M
EOLS icon
75
PUT
Evolus
EOLS
$398M
$602K 0.16%
+50,000
New +$654K
1 2
3
4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.

  • Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
  • Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
  • Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
  • Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
  • Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
  • Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.